Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling ...

Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million. Shares were trading up 6.9% to $43.76 Monday morning The stock has gained ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

Harrow, Inc. recently reported third-quarter 2025 results, highlighting a revenue increase to US$71.64 million and a move from a net loss to a net profit compared to the same period last year. The ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.